We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Spectrum Brands (SPB) to Post Q4 Earnings: What's in Store?
Read MoreHide Full Article
Spectrum Brands Holdings, Inc. (SPB - Free Report) is slated to report fourth-quarter fiscal 2020 results on Nov 13, before the opening bell. In the last reported quarter, the company delivered an earnings surprise of 9.2%. Moreover, its earnings outperformed the Zacks Consensus Estimate by 2.1%, on average, in the trailing four quarters.
The Zacks Consensus Estimate for fiscal fourth-quarter earnings has moved up a penny to $1.19 in the past 30 days. Moreover, this suggests a 5.3% rise from the year-ago quarter’s reported figure. Further, the consensus mark for revenues is pegged at $1,017 million, indicating growth of 2.4% from the figure reported in the year-ago quarter.
Factors to Note
Spectrum Brands’ focus on enhancing marketing activities, improving e-commerce capabilities and optimizing cost structure is likely to have favorably impacted the quarterly performance. The company has been benefiting from its Global Productivity Improvement Plan, which aims at improving operating efficiency and effectiveness.
Markedly, the company has been gaining from solid demand for its products stemming from the ongoing coronavirus crisis. We believe that continued higher sales in Home & Garden, Home & Personal Care and Global Pet Care are likely to have contributed to the company’s top-line performance. The Zacks Consensus Estimate for fiscal fourth-quarter sales in the Home & Garden segment stands at $119 million, indicating 5% growth from the year-ago quarter’s reported figure.
We note that the company has entered the aquatics and reptile space via the Omega Sea buyout, which is now part of its Global Pet Care portfolio of aquatic brands. This is likely to have favorably impacted the Global Pet Care segment. In fact, the Zacks Consensus Estimate for sales in this unit is pegged at $244 million, which implies an increase of 6.6% year over year.
Although the Hardware & Home Improvement segment witnessed soft sales due to COVID-19-related shutdowns in the recent past, the unit is likely to have seen an improvement in the fiscal fourth quarter, driven by housing starts, and repair and remodelling activities.
Spectrum Brands Holdings Inc. Price and EPS Surprise
Our proven model predicts an earnings beat for Spectrum Brands this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Spectrum Brands has a Zacks Rank #2 and an Earnings ESP of +9.24%.
Other Stocks With Favorable Combinations
Here are some other companies you may want to consider, as our model shows that these too have the right combination of elements to post an earnings beat this reporting cycle:
Guess (GES - Free Report) currently has an Earnings ESP of +60.00% and a Zacks Rank #3.
PVH Corp. (PVH - Free Report) presently has an Earnings ESP of +161.64% and a Zacks Rank #3.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Spectrum Brands (SPB) to Post Q4 Earnings: What's in Store?
Spectrum Brands Holdings, Inc. (SPB - Free Report) is slated to report fourth-quarter fiscal 2020 results on Nov 13, before the opening bell. In the last reported quarter, the company delivered an earnings surprise of 9.2%. Moreover, its earnings outperformed the Zacks Consensus Estimate by 2.1%, on average, in the trailing four quarters.
The Zacks Consensus Estimate for fiscal fourth-quarter earnings has moved up a penny to $1.19 in the past 30 days. Moreover, this suggests a 5.3% rise from the year-ago quarter’s reported figure. Further, the consensus mark for revenues is pegged at $1,017 million, indicating growth of 2.4% from the figure reported in the year-ago quarter.
Factors to Note
Spectrum Brands’ focus on enhancing marketing activities, improving e-commerce capabilities and optimizing cost structure is likely to have favorably impacted the quarterly performance. The company has been benefiting from its Global Productivity Improvement Plan, which aims at improving operating efficiency and effectiveness.
Markedly, the company has been gaining from solid demand for its products stemming from the ongoing coronavirus crisis. We believe that continued higher sales in Home & Garden, Home & Personal Care and Global Pet Care are likely to have contributed to the company’s top-line performance. The Zacks Consensus Estimate for fiscal fourth-quarter sales in the Home & Garden segment stands at $119 million, indicating 5% growth from the year-ago quarter’s reported figure.
We note that the company has entered the aquatics and reptile space via the Omega Sea buyout, which is now part of its Global Pet Care portfolio of aquatic brands. This is likely to have favorably impacted the Global Pet Care segment. In fact, the Zacks Consensus Estimate for sales in this unit is pegged at $244 million, which implies an increase of 6.6% year over year.
Although the Hardware & Home Improvement segment witnessed soft sales due to COVID-19-related shutdowns in the recent past, the unit is likely to have seen an improvement in the fiscal fourth quarter, driven by housing starts, and repair and remodelling activities.
Spectrum Brands Holdings Inc. Price and EPS Surprise
Spectrum Brands Holdings Inc. price-eps-surprise | Spectrum Brands Holdings Inc. Quote
What the Zacks Model Unveils
Our proven model predicts an earnings beat for Spectrum Brands this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Spectrum Brands has a Zacks Rank #2 and an Earnings ESP of +9.24%.
Other Stocks With Favorable Combinations
Here are some other companies you may want to consider, as our model shows that these too have the right combination of elements to post an earnings beat this reporting cycle:
Central Garden Pet Company (CENT - Free Report) currently has an Earnings ESP of +57.14% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Guess (GES - Free Report) currently has an Earnings ESP of +60.00% and a Zacks Rank #3.
PVH Corp. (PVH - Free Report) presently has an Earnings ESP of +161.64% and a Zacks Rank #3.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>